Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: A long-term analysis of various treatment regimens

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1583-1592

  Gyurus, E ^a   Kaposztas, Z ^a   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SKIN INFECTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION;

DIABETES MELLITUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 79959483515     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.05.001     Document Type: Article

References (41)

1. B.L. Kasiske, J.J. Snyder, D. Gilbertson, and A.J. Matas Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178
2. E. Sulanc, J.T. Lane, and S.E. Puumala New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines Transplantation 80 2005 945
3. P.T.P. Pham, P.C.T. Pham, G.S. Lipshutz, and A.H. Wilkinson New onset diabetes mellitus after solid organ transplantation Endocrinol Metab Clin North Am 36 2007 873
4. J. Davidson, A. Wilkinson, and J. Dantal New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation 75 10 Suppl 2003 SS3
5. O. Johnston, C.L. Rose, A.C. Webster, and J.S. Gill Sirolimus is associated with new-onset diabetes in kidney transplant recipients J Am Soc Nephrol 19 2008 1411
6. M.L. Bartelink, L. Hoek, J.P. Freriks, and G.E. Rutten Infections in patients with type 2 diabetes in general practice Diabetes Res Clin Pract 40 1998 15
7. V.M. Montori, A. Basu, and P.J. Erwin Posttransplantation diabetes: a systematic review of the literature Diabetes Care 25 2002 583
8. R. Marcen, J.M. Morales, and D. Castillo Posttransplant diabetes mellitus in renal allograft recipients: a prospective multicenter study at 2 years Transplant Proc 38 2006 3530
9. C.J. Driscoll Risk factors for posttransplant diabetes mellitus: a review of the literature Transplant Proc 17 2007 295
10. F. Vincenti, S. Friman, and E. Scheuermann Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus Am J Transplant 7 2007 1506
11. G. Ciancio, G.W. Burke, and J.J. Gaynor A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year Transplantation 77 2004 252
12. T. Shah, A. Kasravi, and E. Huang Risk factors for development of new-onset diabetes mellitus after kidney transplantation Transplantation 82 2006 1673
13. B.D. Kahan Rapamune US Study Group Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study Lancet 356 2000 194
14. B.D. Kahan Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation Transplant Proc 35 3 Suppl 2003 37S
15. R.W. Johnson, H. Kreis, and R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
16. M. Araki, S.M. Flechner, and H.R. Ismail Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs Transplantation 81 2006 335
17. A. Teutonico, P.F. Schena, and S. di Paolo Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus J Am Soc Nephrol 16 2005 3128
18. J. Romagnoli, F. Citterio, and G. Nanni Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine Transplant Proc 38 2006 1034
19. A.S. MacDonald RAPAMUNE Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2001 271
20. B.D. Kahan, K.L. Napoli, and P.A. Kelly Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity Clin Transplant 14 2000 97
21. A.S. Levey, J.P. Bosch, J.B. Lewis Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 1999 461
22. H. Podder, and B.D. Kahan Individualization of immunosuppressive therapy: I Sirolimus improves outcomes in African-American renal transplant recipients Transplant Proc 37 2005 3723
23. J.J. Augustine, and D.E. Hricik Steroid sparing in kidney transplantation: changing paradigms, improving outcomes and remaining questions Clin J Am Soc Nephrol 1 2006 1080
24. S. Chadban New-onset diabetes after transplantationshould it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients Nephrol Dial Transplant 23 2008 1816
25. M.F. Crutchlow, and R.D. Bloom Transplant-associated hyperglycemia: a new look at an old problem Clin J Am Soc Nephrol 2 2007 343
26. K.A. Bodziak, and D.E. Hricik New-onset diabetes mellitus after solid organ transplantation Transpl Int 22 2009 519
27. M. Veroux, D. Corona, and G. Giuffrida New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression Transplant Proc 40 2008 1885
28. Vodenik B, Rovira J, Campistol JM: Mammalian target of rapamycin and diabetes: what does the current evidence tell us?
29. F.B. Craemer, D. Takeda, V. Natu, and C. Sztalryd Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin-and rapamycin-sensitive pathways Metabolism 47 1998 555
30. C.T. Bussiere, J.R.T. Lakey, A.M.J. Shapiro, and G.S. Korbutt The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells Diabetologia 49 2006 2341
31. J.L. Larsen, R.G. Bennett, and T. Burkman Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats Transplantation 82 2006 466
32. M. Cnop, J.C. Hannaert, and A. Hoorens Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation Diabetes 50 2001 1771
33. V. Grill, and A. Bjrklund Impact of metabolic abnormalities for beta cell function: clinical significance and underlying mechanisms Mol Cell Endocrinol 297 2009 86
34. M. Ried, S. Gibbons, and D. Kwok Cyclosporine levels in human tissues of patients treated for one week to one year Transplant Proc 15 1983 2434
35. H. Podder, S.M. Stepkowski, and K. Napoli Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations J Am Soc Nephrol 12 2001 1059
36. S. Di Paolo, A. Teutonico, and Leogrande Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and A.K.T.activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 17 2006 2236
37. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926
38. O.J. Shah, Z. Wang, and T. Hunter Inapropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr Biol 14 2004 1650
39. J.M. Cruzado Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors Transplant Rev 22 2008 73
40. M. Pende, S.C. Kozma, and M. Jaquet Hypoinsulinemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice Nature 408 2000 994
41. N.A. Syed, and R.L. Khandelwal Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells Mol Cel Bichem 211 2000 123